Umecrine Mood AB is developing novel products to treat the mental and physical symptoms associated with Premenstrual Dysphoric Disorder (PMDD) and serve Premenstrual Syndrome (PMS) caused by endogenous CNS-active steroids derived from the corpus luteum of the ovary. The company offers a unique and novel treatment principle based on modulation of GABA-steroid action.
The company portfolio includes newly discovered lead compounds and the selected drug candidate is a first-in-class compound, a non-hormonal selective GABAA receptor modulator, currently in clinical phase I.
The company is part of the Karolinska Development AB (publ).